Curcumin Prevents Acute Neuroinflammation and Long-Term Memory Impairment Induced by Systemic Lipopolysaccharide in Mice by Sorrenti, Vincenzo et al.
fphar-09-00183 March 1, 2018 Time: 15:52 # 1
ORIGINAL RESEARCH
published: 05 March 2018
doi: 10.3389/fphar.2018.00183
Edited by:
Hector J. Caruncho,
University of Victoria, Canada
Reviewed by:
John George Howland,
University of Saskatchewan, Canada
Wladyslaw Lason,
Institute of Pharmacology PAS,
Poland
*Correspondence:
Pietro Giusti
pietro.giusti@unipd.it
Specialty section:
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 24 January 2018
Accepted: 19 February 2018
Published: 05 March 2018
Citation:
Sorrenti V, Contarini G, Sut S,
Dall’Acqua S, Confortin F, Pagetta A,
Giusti P and Zusso M (2018)
Curcumin Prevents Acute
Neuroinflammation and Long-Term
Memory Impairment Induced by
Systemic Lipopolysaccharide in Mice.
Front. Pharmacol. 9:183.
doi: 10.3389/fphar.2018.00183
Curcumin Prevents Acute
Neuroinflammation and Long-Term
Memory Impairment Induced by
Systemic Lipopolysaccharide in Mice
Vincenzo Sorrenti1, Gabriella Contarini1, Stefania Sut2, Stefano Dall’Acqua1,
Francesca Confortin1, Andrea Pagetta1, Pietro Giusti1* and Morena Zusso1
1 Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padua, Italy, 2 Department of
Agronomy, Food, Natural Resources, Animals and the Environment, University of Padova, Padua, Italy
Systemic lipopolysaccharide (LPS) induces an acute inflammatory response in the
central nervous system (CNS) (“neuroinflammation”) characterized by altered functions
of microglial cells, the major resident immune cells of the CNS, and an increased
inflammatory profile that can result in long-term neuronal cell damage and severe
behavioral and cognitive consequences. Curcumin, a natural compound, exerts
CNS anti-inflammatory and neuroprotective functions mainly after chronic treatment.
However, its effect after acute treatment has not been well investigated. In the present
study, we provide evidence that 50 mg/kg of curcumin, orally administered for 2
consecutive days before a single intraperitoneal injection of a high dose of LPS (5 mg/kg)
in young adult mice prevents the CNS immune response. Curcumin, able to enter brain
tissue in biologically relevant concentrations, reduced acute and transient microglia
activation, pro-inflammatory mediator production, and the behavioral symptoms of
sickness. In addition, short-term treatment with curcumin, administered at the time of
LPS challenge, anticipated the recovery from memory impairments observed 1 month
after the inflammatory stimulus, when mice had completely recovered from the acute
neuroinflammation. Together, these results suggest that the preventive effect of curcumin
in inhibiting the acute effects of neuroinflammation could be of value in reducing the long-
term consequences of brain inflammation, including cognitive deficits such as memory
dysfunction.
Keywords: lipopolysaccharide, neuroinflammation, curcumin, microglia, sickness behavior, pro-inflammatory
cytokines, memory impairment
INTRODUCTION
The central nervous system (CNS) immune response (“neuroinflammation”) is emerging as
a crucial component in the etiology and course of major neurodegenerative and psychiatric
disorders (Glass et al., 2010; Najjar et al., 2013; Amor et al., 2014; Ransohoff, 2016). Microglia,
the resident macrophages of the CNS, act as the primary component of an active immune
response. Activated upon exposure to endogenous or exogenous injurious stimuli, these cells
change their morphology, proliferate, upregulate surface molecules, and become an important
source of inflammatory cytokines [e.g., tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6],
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chemokines and other mediators [nitric oxide, prostaglandin E2
and cyclooxygenase-2 (COX-2)] that affect CNS functions
(Dantzer et al., 2008; Agostinho et al., 2010; Kempuraj
et al., 2016). The neuroinflammatory process is normally
transient, with activated microglia returning to a resting
state once the inflammatory stimulus is resolved. Although
an efficient immune response is necessary and critical
for host defense, excessive CNS inflammation and over-
activation of microglia contribute to neuronal cell damage
and exacerbate the severity of neurodegenerative diseases
(Norden et al., 2015). In this context, the resolution of
an acute inflammatory condition appears crucial to avoid
chronic inflammation and ensure appropriate return to tissue
homeostasis.
Despite the presence of a blood–brain barrier, bidirectional
communication between CNS and peripheral immune system
occurs (ThyagaRajan and Priyanka, 2012). Clinical and
experimental studies have shown that both chronic and
acute systemic inflammatory processes can have deleterious
consequences for the brain, representing a risk factor for the
development of permanent CNS dysfunction, mostly in the
aged and vulnerable brain (Cunningham, 2013; Cunningham
and Hennessy, 2015). For example, obesity, diabetes, and
atherosclerosis are chronic conditions with inflammatory
components that increase the risk of Alzheimer’s disease
(Yaffe et al., 2004). Furthermore, acute conditions such as
severe sepsis induce microglial activation and brain damage
in humans and in rodent models (Cunningham, 2013;
Widmann and Heneka, 2014). In recent years, high doses
of systemically injected bacterial lipopolysaccharide (LPS;
5–10 mg/kg) have been extensively used in animal models to
study the interaction between peripheral inflammation and
neurodegenerative disorders. Peripheral LPS induces synthesis
of pro-inflammatory mediators in the brain, resulting in a variety
of central effects, including synaptic dysfunction, neuronal
cell degeneration, and cognitive impairment (Qin et al., 2007,
2013).
Although neuroinflammation is associated with CNS
pathologies, clinical trials using anti-inflammatory drugs have
been disappointing (Imbimbo et al., 2010). Therefore, growing
interest is focused on identifying natural compounds and
dietary factors as potential therapeutic agents in neurological
disorders associated with inflammation. The natural polyphenol
curcumin, the main bioactive component in the rhizome
of the turmeric plant (Curcuma longa), is a safe and highly
pleiotropic molecule with multiple biological targets and a wide
range of beneficial activities, thanks to its anti-inflammatory,
anti-tumor, anti-oxidative, anti-amyloidogenic, metal-chelating,
and cardiovascular protective effects (Hatcher et al., 2008).
Many studies have also reported the neuroprotective effect of
curcumin in cellular and animal models of Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, multiple sclerosis,
depression, and schizophrenia (Lee W.H. et al., 2013). In
addition, epidemiological evidence in countries where curcumin
consumption is widespread points to a lower incidence of
neurodegenerative cases (Ng et al., 2006). The therapeutic
benefit of curcumin has been shown mainly after chronic
treatment (i.e., weeks or months) (Epstein et al., 2010), whereas
short-term administration of curcumin has not been extensively
investigated.
In this study, we applied a widely used mouse model
of systemic inflammation based on a single intraperitoneal
(i.p.) injection of a high dose of LPS to investigate the
prophylactic effect of a short curcumin treatment on acute
neuroinflammation, as well as its impact on long-term memory
impairment.
MATERIALS AND METHODS
Animals
Experiments were carried out using 3-month-old male C57BL/6
mice (Qin et al., 2007), bred in the Animal Facility of the
Department of Pharmaceutical and Pharmacological Sciences,
University of Padova (originally from Charles River, Lecco,
Italy). Mice were housed in individually ventilated plastic cages
(3–5 mice per cage) containing pine-chip bedding and paper
tubes to provide environmental enrichment, under controlled
temperature and humidity, with food and water ad libitum on
a 12-h light/dark cycle (lights on at 7:00 am). Animal-related
procedures were performed in accordance with EU guidelines for
the care and use of laboratory animals and those of the Italian
Ministry of Health (D.Lg. 26/2014). The study was approved by
the Institutional Review Board for Animal Research (Organismo
Preposto al Benessere degli Animali, OPBA) of the University of
Padova and by the Italian Ministry of Health (Protocol number
722/2015-PR).
Experimental Procedures
Animals were adapted to handling once daily for at least 5 days
before any manipulation. During the handling period, mouse
weight and food intake were measured daily. Mice were randomly
divided into four experimental groups: control group treated with
vehicle (control); curcumin group that received only curcumin
treatment (curc); LPS group i.p. injected with LPS (LPS); and
LPS pre-treated with curcumin group (LPS+ curc). All solutions
were prepared fresh on the day of treatment and administered
by gavage or i.p. in a final volume of 0.1–0.15 ml. A suspension
of curcumin (Sigma-Aldrich, Milan, Italy) in 1% methylcellulose
was administered by gavage following periodic fasting once per
day at a dose of 50 mg/kg body weight for 2 consecutive days
(Figure 1). Control animals were treated with the same volume
of vehicle according to the same time schedule. On the second
day of treatment, LPS and LPS + curc groups received a single
i.p. injection of 5 mg/kg of LPS (E. Coli, 026:B6; Sigma-Aldrich,
Milan, Italy), that was administered 1 h after curcumin or vehicle
(Figure 1). Animals from the respective control groups received
an equal volume of vehicle (sterile, endotoxin-free physiological
saline). This dose of LPS is reported to induce an inflammatory
response in the brain, behavioral modifications and a progressive
neurodegeneration in adult rodents (Qin et al., 2007, 2013; Bossù
et al., 2012; Gasparotto et al., 2017). Doses of curcumin up to
100 mg/kg were tested and the lowest effective dose inhibiting
the increase in TNF-α mRNA levels induced by systemic LPS
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FIGURE 1 | Schematic representation of the experimental design of this study. Mice treated for 2 consecutive days with curcumin (curc; 50 mg/kg) received a single
intraperitoneal (i.p.) injection of LPS (5 mg/kg). Control animals received per os the same volume of vehicle following the same time schedule and were then injected
i.p. with saline. At different times after LPS administration, behavioral tests were performed and blood samples and brain tissues were collected for analysis.
was selected for this study (Supplementary Figure 1). Mortality
or significant moribundity requiring euthanasia occurred in less
than 10% of animals following LPS injection. Animals were
assessed in terms of weight, activity in the home cage, and
general appearance at 2, 8, and 24 h and daily for 1 week
after LPS administration. Behavioral testing and molecular and
biochemical analyses were performed at selected time points after
LPS challenge (Figure 1).
Behavioral Testing
Sickness Behavioral Syndrome
Twenty-four hours after i.p. injection of LPS, the presence of
acute sickness behavior symptoms was evaluated by measuring
changes in body weight, food intake, and exploratory locomotor
activity (Godbout et al., 2005; Davis et al., 2017). The amount
of food consumed during the 24-h period was calculated by
subtracting the weight of any uneaten pellets (which remained
on the cage lid and fell into the cage) at the end of the measured
period from that at the beginning.
Open Field Test
The open field test was used to assess exploratory locomotor
activity. Mice were tested in an apparatus consisting of an opaque
open field box (42 cm × 42 cm × 30 cm) constantly illuminated
with a white light (25 ± 5 lux). Each mouse was placed alone
at the center of the open field arena and allowed to move and
explore freely around the arena. During a 10-min session, activity
was video-recorded using a camera mounted above the chamber.
The open field arena was cleaned with 70% ethanol between
each session. Data were analyzed using the ANY-mazeTM video
tracking system (Stoelting Co., Wood Dale, IL, United States)
by a well-trained observer who was blind to the treatment.
Behavioral parameters analyzed included: (1) total distance (m)
traveled in the arena; (2) time (s) spent in the central zone (the
20 cm× 20 cm inner region) of the testing arena.
Novel Object Recognition Test
The novel object recognition test was carried out in the same
apparatus as the open field test. The arena and objects were
cleaned with 70% ethanol before and at the end of each behavioral
evaluation. The task was divided into three different sessions,
each lasting 10 min, and carried out for 2 consecutive days.
In the first session (habituation session), mice were individually
habituated to the open-field apparatus and then returned to their
home cage. Twenty-four hours later, during the training session,
mice were individually placed in the arena, exposed to two
identical plastic objects (rectangular boxes, 3 cm× 3 cm× 6 cm)
placed in two corners of the open field apparatus, 8 cm from
the sidewalls. The exploration time was video-recorded using a
camera mounted above the chamber. Exploration was recorded
when the animal touched or reached the objects with the nose at
a distance of less than 1 cm. Climbing or sitting on the object was
not considered exploration (Frühauf et al., 2015). Immediately
after this session, the animal was returned to its home cage. Two
hours after the training session, mice were placed back into the
arena with two objects: one identical to the familiar object but
previously unused to prevent olfactory cues and one novel object
of a different shape and color, but similar in size (laboratory
flask, 4 cm × 3 cm × 6 cm) (testing session). The time spent
exploring each object was recorded. Data were analyzed using
the ANY-maze video-tracking system (Stoelting Co.) by a well-
trained observer who was blind to the treatment. Animals that
failed to complete a minimum of 2 s of exploration during either
the training or testing phase were excluded from analysis. The
preference index was then calculated, considering the difference
in time spent exploring the novel and familiar objects, using the
formula:
Tnovel
/
(Tnovel + Tfamiliar)
The preference index was used as a memory parameter.
Tissue Collection
At different time points after LPS/saline injection, mice were
rapidly euthanized by cervical dislocation, minimizing suffering,
discomfort, or stress. To measure curcumin concentration,
immediately after sacrifice, blood samples were collected by
cardiac puncture for separation of plasma, which was stored at
−80◦C. Animals were then decapitated, whole brains removed
and immediately used or frozen in liquid nitrogen and stored at
−80◦C until analysis.
To measure mRNA expression of target genes after
decapitation, brain regions (cortex, striatum, hippocampus,
and cerebellum) were dissected out based on stereological
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coordinates using a mouse brain atlas (Franklin and Paxinos,
2007; Sorrenti et al., 2018), frozen in liquid nitrogen and stored
at−80◦C until further analysis.
For immunofluorescence studies, mice were anesthetized with
isoflurane and perfused via the cardiovascular system with saline
followed by 4% paraformaldehyde (Sigma-Aldrich). Brains were
removed intact, post-fixed with 4% paraformaldehyde for 2 h at
4◦C, dehydrated through an ascending sucrose series (15 and 30%
sucrose) at 4◦C overnight and then embedded in Tissue-Tek OCT
compound (Sakura Finetek, Torrance, CA, United States). The
embedded brains were kept at−80◦C until sectioning.
Liquid Chromatography/Mass
Spectrometry (LC/MS)
Plasma and brain tissues were extracted in methanol and
analyzed by HPLC/MS using benzanilide as an internal standard.
Whole brains were homogenized in 500 µl of methanol
and 300 µl of internal standard stock solution (100 µg/ml
benzanilide in methanol) and sonicated for 5 min at room
temperature. Samples were then centrifuged at 13,000 rpm
for 20 min and supernatant was used for analysis. Two-
hundred microliter of plasma samples were extracted in 500 µl
of methanol and 200 µl of internal standard stock solution.
Samples were vortexed and centrifuged at 13,000 rpm for
20 min.
Analysis was carried out using an Agilent 1260 Series
HPLC chromatograph equipped with a Prostar 410 autosampler
(Varian, Inc., Palo Alto, CA, United States) and coupled
with a Varian 320 TQD MS spectrometer (Varian). The mass
spectrometer was equipped with an electrospray ionization (ESI)
source as the interface and analysis was conducted in positive
ion mode. Analyses were performed on a Phenomenex Kinetex
EVO C-18 100A, 100 mm× 3mm 5µ column. The mobile phase
was (A) water-formic acid (100:2.0 v/v) and (B) acetonitrile.
A gradient program was used, as follows: 0→ 1st min A:B (95:5)
isocratic; 1→ 15th min: A:B (5:95); 15→ 20th min A:B (5:95)
isocratic; 20→ 25th min, return to initial conditions. The mobile
phase flow rate was 400 µl/min; the flow was split after the
column and 200 µl/min were direct injected in the ESI source.
The injection volume was 5 µl.
Quantification was performed using multiple reaction
monitoring (MRM) with m/z 369 → 177 transition for
curcumin, m/z 449 → 177 for curcumin sulfate, m/z 545 →
177 for curcumin glucuronide and m/z 198 → 105 transition
for ISTD benzanilide. The MS parameters were capillary voltage
120 V, needle voltage 4,500 V, shield voltage 350 V, collision
energy 15 V, Q1 voltage 1.2 V and Q3 voltage 20.0 V, nebulising
gas pressure 15 psi, and drying gas pressure 20 psi.
Curcumin standard solution was prepared at different
concentrations 10 µg/ml → 0.1 µg/ml and benzanilide (ISTD)
stock solution was diluted 1:10 (50 µg/ml → 0.1 µg/ml). The
calibration curve was obtained mixing 500 µl of 0.1 µg/ml ISTD
with different volumes (500, 400, 300, 200, 100, and 50 µl) of
0.1 µg/ml curcumin standard solution in order to obtain different
curcumin/benzanilide quantity ratios for the calibration curve.
Detection limits were 0.09 ng/ml and 0.03 ng/g on plasma and
brain tissue, respectively.
RNA Isolation and Real-Time PCR
Total RNA was extracted from tissues using TRIzol (Invitrogen,
Milan, Italy), according to the manufacturer’s instructions. RNA
integrity and quantity were determined by RNA 6000 Nano
assay in an Agilent Bioanalyzer (Thermo Fisher Scientific, Milan,
Italy). Samples were reverse transcribed with Superscript III
reverse transcriptase (Invitrogen). The real-time-PCR reaction
was performed as described previously (Barbierato et al., 2015).
Primer sequences are listed in Table 1. The amounts of each
gene product were calculated using linear regression analysis
from standard curves, demonstrating amplification efficiencies
ranging from 90 to 100%. Dissociation curves were generated
for each primer pair, showing single-product amplification. Data
are presented as specific ratio between the gene of interest and
the reference gene (glyceraldehyde-3-phosphate dehydrogenase,
GAPDH) normalized to vehicle-treated group (control).
Immunofluorescence and Image Analysis
Using a−20◦C cryostat (Leica Microsystems, Wetzlar, Germany),
frozen tissues were sliced into 14-µm coronal sections, mounted
onto Superfrost glass slides (Thermo Fisher Scientific, Milan,
Italy) and stored at −20◦C until use. Non-specific staining was
blocked by incubating with 5% normal goat serum and 0.1%
Triton X-100 in PBS for 1 h at room temperature. Sections were
then incubated sequentially with anti-ionized calcium binding
adaptor molecule 1 (Iba1) primary antibody (1:800; Wako Pure
Chemical Industries, Ltd., Japan) for 2 h, followed by Alexa
Fluor 488 fluorescent-conjugated secondary antibody (1:1000;
Invitrogen) for 1 h in the above blocking solution (Zusso
et al., 2012). Slides were thoroughly washed between steps
with PBS. The coverslips were mounted on microscope slides
with Fluoromount-G mounting medium (SouthernBiotech,
United States). Immunostaining controls included omission of
the primary antibody. Images were captured with a confocal
laser-scanning microscope (Zeiss LSM 800; Carl Zeiss AG,
Germany) and microscope settings were kept constant for all
images. The Iba1 fluorescence intensity was measured using
the ImageJ software (Fiji, version 1.51n; National Institutes
TABLE 1 | Primers for real-time PCR used in this study.
Gene target Primer name Sequence (5′–3′)
TNF-α TNF-α For CAAGTGGAGGAGCAGCTGGA
TNF-α Rev CATCGGCTGGCACCACTAGT
IL-1β IL-1β For CTGGTGTGTGACGTTCCCATTA
IL-1β Rev CCGACAGCACGAGGCTTT
IL-6 IL-6 For GAGGATACCACTCCCAACAGACC
IL-6 Rev AAGTGCATCATCGTTGTTCATACA
COX-2 COX-2 For GCTGGCCTGGTACTCAGTAGGTT
COX-2 Rev CGAGGCCACTGATACCTATTGC
NLRP3 NLRP3 For CCTGACCCAAACCCACCAGT
NLRP3 Rev AGACCTCCCCAATGTGCTCG
CD16 CD16 For GCAGCAACTTTTCAGCCACA
CD16 Rev GAACTGGCGATCCTCCTTCC
GAPDH GAPDH For TGGTGAAGGTCGGTGTGAAC
GAPDH Rev AATGAAGGGGTCGTTGATGG
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of Health, United States), after subtracting background levels.
For comparison among different groups, immunofluorescence
intensity was quantified within defined areas of the cerebral
cortex (Bhat et al., 2017). Microglial cell density was calculated
by counting the number of Iba1-positive cells in the images and
expressed as cell number/mm2. All areas were measured using
the ImageJ software. Six sections per mouse from five different
mice per experimental group were analyzed and each section was
50 µm from the previous section. All analyses were performed by
an investigator blind to the experimental conditions.
Statistical Analysis
Statistical analysis was performed using GraphPad Software,
version 3.03 (GraphPad Software Inc., La Jolla, CA,
United States). Results are expressed as mean ± SEM. Data
were analyzed by Student’s t-test for comparisons involving two
groups or by one-way analysis of variance (ANOVA) followed by
Bonferroni’s post hoc test for multiple comparisons. A value of
p < 0.05 was considered to be statistically significant. Additional
details are provided in the figure legends, where appropriate.
RESULTS
Plasma and Brain Concentrations of
Curcumin
Given curcumin’s poor oral bioavailability, we first assessed
its ability to reach the CNS for short treatment times. Mice
were orally treated with 50 mg/kg curcumin once daily for 2
consecutive days and then i.p. injected with 5 mg/kg LPS or
vehicle. Two hours after LPS injection, mice were sacrificed
and the plasma and brain tissue analyzed by LC/MS. Brain
concentration of curcumin was 41.1 ± 6.7 ng/g. Curcumin
metabolism was also examined. Brain levels of the metabolite
curcumin sulfate were not significantly different from the
concentration of the parent compound. Moreover, low levels
of the glucuronide metabolite were detected in brain tissues
(3.1 ± 1.6 ng/g). LC/MS analysis revealed that plasma contained
very low concentrations of curcumin (8.2 ± 1.8 ng/g),
with the sulfate and glucuronide metabolites being more
abundant (67.0 ± 10.2 ng/ml and 453.2 ± 110.2 ng/ml,
respectively). LPS treatment did not significantly modify brain
and plasma levels of either curcumin or its metabolites
(Table 2).
Effect of Curcumin on the Acute CNS
Pro-inflammatory Response to
Peripheral LPS Administration
To evaluate the effect of curcumin on the LPS-induced
CNS immune response, the mRNA expression of several key
pro-inflammatory mediators, such as TNF-α, IL-1β, NLRP3
inflammasome, IL-6, and COX-2 was evaluated in different brain
areas, as an index of inflammation. Mice were pre-treated with
curcumin once daily for 2 days before a single i.p. injection of
LPS. All tested mRNAs increased 2 h following LPS injection
in the cortex, striatum, hippocampus, and cerebellum (black
bars, Figure 2). Pre-treatment with curcumin reduced the LPS-
induced increased levels of TNF-α, IL-1β, NLRP3 inflammasome,
and COX-2 in all brain areas, while reducing the expression of
IL-6 to more selected regions (striatum and cerebellum) (dark
gray bars, Figure 2), suggesting a protective effect of curcumin
against LPS-induced brain inflammation. mRNA expression did
not differ between vehicle- (white bars, Figure 2) and curcumin-
treated (light gray bars, Figure 2) mice. Starting from 24 h after
LPS administration, mRNA expression levels for all genes in
LPS-treated mice returned to control levels (data not shown),
suggesting a resolution of inflammation.
Effect of Curcumin on Acute Microglial
Activation in Response to Peripheral LPS
Administration
Upon activation, microglia alter their morphology and functional
properties in response to environmental changes, a process that
is a hallmark of neuroinflammation (Marshall et al., 2013).
Since microglial activation is associated with up-regulation of
the constitutively expressed marker Iba1, its expression was
analyzed in the cerebral cortex 2 h following LPS challenge.
The number of Iba1-expressing cells displaying a morphology
associated with activated microglia increased after LPS treatment,
whereas curcumin pre-treatment completely prevented this
effect (Figures 3A,B). These results were supported by the
quantification of Iba1 staining intensity (Figure 3C).
Another feature of pro-inflammatory microglial cell activation
is increased expression of the cluster of differentiation 16 (CD16),
an M1-phenotype marker (Fumagalli et al., 2015; Yang et al.,
2017). As expected, LPS induced an increase in CD16 mRNA
expression, which returned to control value with curcumin
treatment (Figure 3D).
TABLE 2 | Detection of curcumin and its metabolites in brain and plasma.
Brain Plasma
Treatment Curcumin (ng/g) Curcumin sulfate
(ng/g)
Curcumin
glucuronide (ng/g)
Curcumin (ng/ml) Curcumin sulfate
(ng/ml)
Curcumin
glucuronide (ng/ml)
Curcumin 41.1 ± 6.7 42.5 ± 5.1 3.1 ± 1.6 8.2 ± 1.8 67.0 ± 10.2 453.2 ± 110.2
Curcumin + LPS 108.3 ± 25.8 35.4 ± 3.0 2.4 ± 0.9 4.8 ± 0.9 35.3 ± 10.8 348.0 ± 32.7
Data show brain and plasma concentrations of curcumin, curcumin sulfate, and curcumin glucuronide 3 h after administration via gavage. Data are mean ± SEM (n = 3–5
animals/group). Data were analyzed by Student’s t-test [brain curcumin, t(5) = 2.17, p = 0.08; brain curcumin sulfate, t(8) = 1.72, p = 0.12; brain curcumin glucuronide,
t(7) = 0.44, p = 0.67; plasma curcumin, t(6) = 1.90, p = 0.10; plasma curcumin sulfate, t(5) = 2.06, p = 0.09; plasma curcumin glucuronide, t(5) = 1.05, p = 0.34].
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FIGURE 2 | Curcumin inhibits the acute brain pro-inflammatory response to peripheral LPS administration. Mice treated for 2 consecutive days with curcumin (curc;
50 mg/kg) received a single i.p. injection of LPS (5 mg/kg). Two hours following LPS or saline injection, mice were sacrificed and cerebral cortex, striatum,
hippocampus, and cerebellum were extracted and prepared as described in Section “Materials and Methods.” (A) Analysis of TNF-α mRNA expression levels was
conducted via real-time PCR. Results are expressed as fold-increase with respect to control (vehicle only). Data are means ± SEM (n = 4 mice/group). Data were
analyzed by one-way ANOVA [F(15,48) = 32.89, p < 0.0001] followed by Bonferroni’s multiple comparison test. ∗∗∗p < 0.001 vs. control group; ##p < 0.01 and
###p < 0.001 vs. LPS-stimulated group. (B) Analysis of IL-1β mRNA expression levels was conducted via real-time PCR. Results are expressed as fold-increase with
respect to control (vehicle only). Data are means ± SEM (n = 4 mice/group). Data were analyzed by one-way ANOVA [F(15,48) = 59.32, p < 0.0001] followed by
Bonferroni’s multiple comparison test. ∗∗∗p < 0.001 vs. control group; ###p < 0.001 vs. LPS-stimulated group. (C) Analysis of NLRP3 mRNA expression levels was
conducted via real-time PCR. Results are expressed as fold-increase with respect to control (vehicle only). Data are means ± SEM (n = at least 4 mice/group). Data
were analyzed by one-way ANOVA [F(15,54) = 26.21, p < 0.0001] followed by Bonferroni’s multiple comparison test. ∗∗∗p < 0.001 vs. control group; #p < 0.05 and
##p < 0.01 vs. LPS-stimulated group. (D) Analysis of IL-6 mRNA expression levels was conducted via real-time PCR. Results are expressed as fold-increase with
respect to control (vehicle only). Data are means ± SEM (n = 4 mice/group). Data were analyzed by one-way ANOVA [F(15,48) = 49.62, p < 0.0001] followed by
Bonferroni’s multiple comparison test. ∗p < 0.05, ∗∗p < 0.01 and ∗∗∗p < 0.001 vs. control group; ###p < 0.001 vs. LPS-stimulated group. (E) Analysis of COX-2
mRNA expression levels was conducted via real-time PCR. Results are expressed as fold-increase with respect to control (vehicle only). Data are means ± SEM
(n = 4 mice/group). Data were analyzed by one-way ANOVA [F(15,48) = 45.03, p < 0.0001] followed by Bonferroni’s multiple comparison test. ∗∗p < 0.01 and
∗∗∗p < 0.001 vs. control group; #p < 0.05 and ##p < 0.01 and ###p < 0.001 vs. LPS-stimulated group.
Effect of Curcumin on Acute Sickness
Behavior Syndrome Induced by
Peripheral LPS Administration
Pro-inflammatory cytokines released by activated microglia are
responsible for the behavioral symptoms of sickness, including
reduced body weight, food and water intake, motor and social
activities, and altered cognition that usually are observable during
the first 24–48 h after LPS treatment (Kelley et al., 2003; Dantzer
et al., 2008; Kang et al., 2017; Zager et al., 2018). Systemic LPS
induced a reduction of body weight and food intake 24 h after
treatment and curcumin protected against LPS-associated weight
loss and anorexia (Figures 4A,B). Furthermore, and in agreement
with previous studies (Dantzer et al., 2008; Davis et al., 2017),
LPS diminished the distance traveled and the amount of time
that mice spent in the central area of the open-field arena (black
bars, Figures 4C,D). Curcumin pre-treatment prevented the
reduction of locomotion (dark gray bars, Figure 4C) and induced
a slight increase, although not statistically significant, in the time
spent in the central area (dark gray bars, Figure 4D). Seven
days after LPS administration, behavioral symptoms of sickness
returned to control levels (data not shown), with the exception of
distance traveled in the arena that was still significantly reduced
(Figure 4E).
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FIGURE 3 | Curcumin inhibits acute microglial cell activation in response to peripheral LPS administration. Mice treated for 2 consecutive days with curcumin (curc;
50 mg/kg) received a single i.p. injection of LPS (5 mg/kg). Two hours following LPS or saline injection, mice were sacrificed and the whole brain, cerebral cortex,
striatum, hippocampus, and cerebellum were extracted and prepared as described in Section “Materials and Methods.” (A) Schematic of the cerebral cortex in the
coronal plane indicating the location (red square) of the area examined and representative images of Iba1-stained microglia through the cortex from the four
experimental groups. Scale bar, 50 µm. (B) Bar graphs representing the quantification of the number of Iba1+ microglia in the cerebral cortex. Data are
means ± SEM (n = 5 mice/group). Data were analyzed by one-way ANOVA [F(3,16) = 17.81, p < 0.0001] followed by Bonferroni’s multiple comparison test.
∗p < 0.05 vs. control group; ##p < 0.01 vs. LPS-stimulated group. (C) Bar graphs representing the quantification of the mean fluorescence intensity of microglia
(Iba1+) in the cerebral cortex. Data are means ± SEM (n = 5 mice/group). Data were analyzed by one-way ANOVA [F(3,16) = 5.52, p < 0.0001] followed by
Bonferroni’s multiple comparison test. ∗∗∗p < 0.001 vs. control group; ###p < 0.001 vs. LPS-stimulated group. (D) Mice treated as described above were sacrificed
24 h following LPS or saline injection. Brain areas were extracted and prepared as described in Section “Materials and Methods” and analysis of CD16 mRNA
expression levels was conducted via real-time PCR. Data are means ± SEM (n = 4 mice/group). Data were analyzed by one-way ANOVA [F(15,64) = 11.18,
p < 0.0001] followed by Bonferroni’s multiple comparison test. ∗∗∗p < 0.001 vs. control group; #p < 0.001 vs. LPS-stimulated group ∗p < 0.05 and ∗∗∗p < 0.001
vs. control group; #p < 0.05 and ###p < 0.001 vs. LPS-stimulated group.
Frontiers in Pharmacology | www.frontiersin.org 7 March 2018 | Volume 9 | Article 183
fphar-09-00183 March 1, 2018 Time: 15:52 # 8
Sorrenti et al. Curcumin Prevents Neuroinflammation and Memory Deficits
FIGURE 4 | Curcumin attenuates the acute symptoms of sickness behavior caused by peripheral LPS administration. Mice treated for 2 consecutive days with
curcumin (curc; 50 mg/kg) received a single i.p. injection of LPS (5 mg/kg). (A) Twenty-four hours following LPS or saline injection, body weight was measured as
described in Section “Materials and Methods.” Data are means ± SEM (n = at least 7 mice/group). Data were analyzed by one-way ANOVA [F(3,28) = 97.03,
p < 0.0001] followed by Bonferroni’s multiple comparison test. ∗∗∗p < 0.001 vs. control group; #p < 0.05 vs. LPS-stimulated group. (B) Twenty-four hours following
LPS or saline injection, the amount of food intake was measured as described in Section “Materials and Methods.” Data are means ± SEM (n = 7 mice/group). Data
were analyzed by one-way ANOVA [F(3,24) = 136.30, p < 0.0001] followed by Bonferroni’s multiple comparison test. ∗∗∗p < 0.001 vs. control group; #p < 0.05 vs.
LPS-stimulated group. (C) Twenty-four hours following LPS or saline injection, total distance traveled was measured as described in Section “Materials and
Methods.” Data are means ± SEM (n = at least 7 mice/group). Data were analyzed by one-way ANOVA [F(3,34) = 10.98, p < 0.0001] followed by Bonferroni’s
multiple comparison test. ∗p < 0.05 and ∗∗∗p < 0.001 vs. control group; #p < 0.05 vs. LPS-stimulated group. (D) Twenty-four hours following LPS or saline
injection, amount of time spent in the central area of the open field arena was measured as described in Section “Materials and Methods.” Data are means ± SEM
(n = 7 mice/group). Data were analyzed by one-way ANOVA [F(3,24) = 24.58, p < 0.0001] followed by Bonferroni’s multiple comparison test. ∗∗∗p < 0.001 vs.
control group. (E) Seven days after LPS treatment, total distance traveled was also measured. Data are means ± SEM (n = at least 7 mice/group). Data were
analyzed by one-way ANOVA [F(4,43) = 4.33, p = 0.0094] followed by Bonferroni’s multiple comparison test. ∗p < 0.05 vs. control group.
Effect of Curcumin on Long-Term
Memory Impairment Induced by
Peripheral LPS Administration
We next investigated whether curcumin, administered
immediately before the LPS treatment, can ameliorate the
effect of LPS on long-term memory function, using the novel
object recognition test, a widely used model to study memory
alterations by measuring recognition memory, attention,
and preference for novelty in rodents (Goulart et al., 2010;
Antunes and Biala, 2012). One month after treatment, when
the acute inflammatory effects of LPS (e.g., mRNA levels of
pro-inflammatory markers and sickness behavior symptoms)
had completely recovered (data not shown), LPS-treated mice
exhibited reduced recognition of a novel object compared to the
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FIGURE 5 | Curcumin inhibits long-term memory deficits induced by
peripheral LPS administration. Mice treated for 2 consecutive days with
curcumin (curc; 50 mg/kg) received a single i.p. injection of LPS (5 mg/kg).
(A) One and three months following LPS or saline injection, mice were subject
to the novel object recognition test and the preference index, used as a
recognition memory parameter, was calculated as described in Section
“Materials and Methods.” Data are means ± SEM (n = at least 7 mice/group).
Data were analyzed by one-way ANOVA [F(7,52) = 3.04, p = 0.0094] followed
by Bonferroni’s multiple comparison test. ∗p < 0.05 vs. control group.
(B) One and three months following LPS or saline injection, mice were subject
to the open field test to measure total distance traveled in the arena. Data are
means ± SEM (n = at least 7 mice/group). Data were analyzed by one-way
ANOVA [F(7,65) = 0.68, p = 0.69] followed by Bonferroni’s multiple comparison
test. ns, not significant.
control mice (left graph, Figure 5A). This effect was completely
restored 3 months after LPS challenge (right graph, Figure 5A).
On the other hand, pre-treatment with curcumin improved
to control value the recognition memory 1 month after LPS
treatment (left graph, Figure 5A), suggesting a role of curcumin
in preventing the memory impairment induced by peripheral
LPS. Since the preference index may be affected by locomotor
impairments unrelated to memory function, we monitored the
distance traveled in the open field arena that was unmodified by
treatments (Figure 5B).
DISCUSSION
Curcumin can interact and modulate the activity of a wide
range of target molecules involved in both acute and chronic
inflammation (Aggarwal et al., 2007; Aggarwal and Harikumar,
2009). Furthermore, considering that curcumin can cross the
blood–brain barrier (Yang et al., 2005; Begum et al., 2008;
Vergoni et al., 2009; Tsai et al., 2011; Hoppe et al., 2013),
it can modulate the inflammatory response also in the CNS.
Using different experimental models of neuroinflammation and
neurodegeneration, many studies have evaluated the protective
effects of a long-term treatment with curcumin (Liu et al.,
2013; Sharma et al., 2017). In contrast, short-term treatments
have not been extensively investigated. In the present study, we
hypothesized that a short treatment with curcumin, administered
to adult mice before an inflammatory challenge, would prevent
the effects on neuroinflammation and microglia activation.
Since curcumin has poor bioavailability, short serum half-
life, and chemical instability in aqueous solution due to the
presence of the 1,3-diketone moiety in its structure (Pan
et al., 1999; Oliveira et al., 2015; Zusso et al., 2017), we
developed an administration protocol to optimize the curcumin
pharmacokinetics and possibly the therapeutic effect. Curcumin
was administered daily, for 2 consecutive days, via gavage in
a 1% methylcellulose suspension, to animals fasted overnight
to facilitate oral absorption of curcumin (Begum et al., 2008).
A dose of 50 mg/kg of curcumin was selected, based on a dose-
response study showing this dose to be the lowest that reduces
LPS-induced gene expression of the pro-inflammatory cytokine
TNF-α. This dose corresponds to a daily intake of approximately
3–4 g for humans and is considered safe and well-tolerated,
as reported by clinical trials showing safety up to 8 g/day of
curcumin for 3 months (Chainani-Wu, 2003). LC/MS analysis
revealed that curcumin entered brain tissue unmodified 3 h
after oral administration, reaching concentrations relevant to its
biological activity (Yang et al., 2005). Conversely, at the same time
point, the plasma concentration of curcumin was approximately
fivefold lower than that of the brain. Vice versa, plasma contained
higher concentrations of the sulfate and glucuronide metabolites
of orally given curcumin than the brain. In particular, the
glucuronide metabolite levels were ∼50-fold higher than those
of the parent compound.
The central effect of these brain curcumin levels was evaluated
using a standard paradigm of neuroinflammation, based on
systemic LPS injection (Kitazawa et al., 2005; Qin et al., 2007).
Data on the levels of pro-inflammatory cytokines in the brain,
changes in the function and structure of the blood–brain barrier,
and neurodegenerative effects after peripheral treatment with
LPS are rather discordant in the literature, possibly due to the
various experimental protocols used (Catorce and Gevorkian,
2016; Varatharaj and Galea, 2017). Here, we used a single
i.p. administration of a high dose of LPS, which stimulated
a prompt and transient increase in mRNA expression of pro-
inflammatory markers (TNF-α, IL-1β, IL-6, NLRP3, and COX-2)
in different brain areas that returned to control levels by 24 h.
Mice treated with LPS showed also an acute sickness response
that included loss of body weight, anorexia, and reduction of
motor activity, as previously reported (Kelley et al., 2003; Dantzer
et al., 2008; Kang et al., 2017; Zager et al., 2018). Furthermore,
LPS induced anxiety-like behavior. Mice are naturally diffident
about entering open or unprotected spaces (Bailey and Crawley,
2009), and the reduced time spent in the central area of the
Frontiers in Pharmacology | www.frontiersin.org 9 March 2018 | Volume 9 | Article 183
fphar-09-00183 March 1, 2018 Time: 15:52 # 10
Sorrenti et al. Curcumin Prevents Neuroinflammation and Memory Deficits
test arena can be interpreted as anxiety-like behavior (Salazar
et al., 2012). Further, brain tissues from these mice showed
an increased number and reactivity of microglia. Activated
microglia have two major phenotypes: M1/pro-inflammatory and
M2/anti-inflammatory (Sochocka et al., 2017). M1 activation,
involved in the progression of neurodegenerative diseases,
causes the release of pro-inflammatory cytokines with increased
expression of a cluster of differentiation markers, including
CD16 (Yang et al., 2017). Pre-treatment with curcumin
prevented LPS-induced M1 microglial cell activation and
related sickness behavioral symptoms, except for the anxiety-
like behavior. However, further investigation using additional
tests of anxiety-like behavior (e.g., elevated plus maze) are
needed to better evaluate the effect of curcumin on LPS-induced
anxiety.
Curcumin has many molecular targets underlying its anti-
inflammatory properties (Aggarwal et al., 2007; Aggarwal and
Harikumar, 2009; He et al., 2015), including acting as an
inhibitor of the nuclear translocation of the transcription
factor NF-κB, which controls the final immune response
via expression of several inflammatory genes (Lu et al.,
2008; Fu et al., 2014). Furthermore, curcumin could have
inhibited the LPS-induced inflammatory response by decreasing
expression of Toll-like receptor 4 (Fu et al., 2014), the
pattern-recognition receptor that binds LPS and plays a crucial
role in the innate immune response (Kawai and Akira,
2010).
Current evidence suggests that inflammatory cytokines lead
to memory and cognitive deficits in rodents and humans.
LPS can affect memory and cognitive functions in different
behavioral paradigms in both rats and mice (Reichenberg et al.,
2001; Jacewicz et al., 2009; Ownby, 2010; Bossù et al., 2012;
Kawamoto et al., 2013; Lee Y.J. et al., 2013; Zhang et al.,
2015). However, these effects have been mostly observed as
early consequences of LPS treatment (usually by 7 days), when
behavioral symptoms of sickness could be present and locomotor
activity reduced, as in our experimental conditions. Here, we
observed an impairment of object-recognition memory 1 month
after LPS challenge, after complete recovery from sickness
behavior and motor dysfunction. In this study, memory deficits
were restored by 3 months post-LPS, in contrast with some
previous studies which described significant memory deficits 3
and also 10 months post-LPS (Semmler et al., 2007; Bossù et al.,
2012). This discrepancy may reflect differences in experimental
conditions, such as animal species (rats or mice), age (young
vs. aged animals), dose of LPS, site (intravenous or i.p.), and
the number of LPS injections or behavioral paradigms used. In
particular, Semmler et al. (2007) and Bossù et al. (2012) used
rat models of sepsis and described memory deficits up to 3 and
10 months after LPS injection, respectively. To the best of our
knowledge, the present findings are the first to show that short-
term treatment with curcumin, administered immediately before
LPS challenge, anticipates the recovery from delayed memory
dysfunction.
Collectively, our results show that a short treatment
with curcumin has a preventive effect on both LPS-induced
acute neuroinflammation and long-term memory impairment,
suggesting that the inhibitory effect on the neuroinflammatory
response may reduce consequent cognitive deficits. These results
support the potential usefulness of curcumin for treatment of
memory and other cognitive deficits evident in many CNS
disorders.
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